An ATRActive Future for Differentiation Therapy in AML

Overview

Journal Blood Rev

Publisher Elsevier

Specialty Hematology

Date 2015 Jan 30

PMID 25631637

Citations 33

Authors

Daniel E Johnson

Robert L Redner

Affiliations

Soon will be listed here.

Abstract

The success of all-trans retinoic acid (ATRA) therapy in acute promeylocytic leukemia (APL) has spawned numerous attempts to translate the paradigm of differentiation therapy to non-APL acute myelocytic leukemia (AML). However, the results of clinical trials have been overall disappointing. In this review we discuss the mechanism of retinoic acid signaling and the results of major clinical trials that have attempted to incorporate ATRA into AML regimens. We discuss recent evidence that indicate that the retinoic acid signaling pathway may be dysfunctional in AML. Preliminary studies suggest that targeting the pathways that modify retinoic acid receptor activity may reactivate the dormant retinoic acid-signaling pathway. Such strategies may revive the ability of ATRA to induce myeloid differentiation and apoptosis in non-APL AML.

Citing Articles

Norchelerythrine from (Thunb.) Pers. promotes differentiation and apoptosis by activating DNA damage response in acute myeloid leukemia.

Lee J, Jeon B, Kwon C, Kim H, Kim T, Seo Y Int J Oncol. 2025; 66(3).

PMID: 39918000 PMC: 11837901. DOI: 10.3892/ijo.2025.5723.

DNA Damage-Inducing 10-Methoxy-canthin-6-one (Mtx-C) Promotes Cell Cycle Arrest in G/M and Myeloid Differentiation of Acute Myeloid Leukemias and Leukemic Stem Cells.

Torquato H, Rodrigues Junior M, Lima C, de Araujo Junior R, Soares C, Domiciano A ACS Omega. 2024; 9(35):37343-37354.

PMID: 39246489 PMC: 11375717. DOI: 10.1021/acsomega.4c05435.

Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.

Wang J, Tan J, Wu B, Wu R, Han Y, Wang C J Nanobiotechnology. 2023; 21(1):374.

PMID: 37833748 PMC: 10571362. DOI: 10.1186/s12951-023-02094-9.

Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.

Liccardo F, Sniegocka M, Tito C, Iaiza A, Ottone T, Divona M J Exp Clin Cancer Res. 2023; 42(1):223.

PMID: 37653435 PMC: 10469880. DOI: 10.1186/s13046-023-02793-z.

The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.

Nagai Y, Ambinder A Cancers (Basel). 2023; 15(14).

PMID: 37509198 PMC: 10377082. DOI: 10.3390/cancers15143535.

References

Fredly H, Ersvaer E, Olsnes Kittang A, Tsykunova G, Gjertsen B, Bruserud O . The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. 2013; 5(1):13. PMC: 3765924. DOI: 10.1186/1868-7083-5-13. View

Soriano A, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F . Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110(7):2302-8. DOI: 10.1182/blood-2007-03-078576. View

Srinivas H, Xia D, Moore N, Uray I, Kim H, Ma L . Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J. 2006; 395(3):653-62. PMC: 1462695. DOI: 10.1042/BJ20051794. View

Tanaka T, Rodriguez de la Concepcion M, De Luca L . Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem Pharmacol. 2001; 61(11):1347-55. DOI: 10.1016/s0006-2952(01)00600-1. View

Nasr R, de The H . Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol. 2010; 91(5):742-7. DOI: 10.1007/s12185-010-0582-0. View

Balmer J, Blomhoff R . Gene expression regulation by retinoic acid. J Lipid Res. 2002; 43(11):1773-808. DOI: 10.1194/jlr.r100015-jlr200. View

Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K . Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005; 104(12):2717-25. DOI: 10.1002/cncr.21589. View

Qian S, Li J, Hong M, Qiu H, Fan L, Xu W . Acute myeloid leukemia in four patients with t(8;21) treated with all-trans retinoic acid as a single agent. Leuk Lymphoma. 2008; 49(5):998-1001. DOI: 10.1080/10428190801959018. View

Bastien J, Rochette-Egly C . Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004; 328:1-16. DOI: 10.1016/j.gene.2003.12.005. View

10.

Nagy L, Kao H, Chakravarti D, Lin R, Hassig C, Ayer D . Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997; 89(3):373-80. DOI: 10.1016/s0092-8674(00)80218-4. View

11.

Evans R . The steroid and thyroid hormone receptor superfamily. Science. 1988; 240(4854):889-95. PMC: 6159881. DOI: 10.1126/science.3283939. View

12.

Burnett A, Hills R, Milligan D, Goldstone A, Prentice A, McMullin M . Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2009; 28(4):586-95. DOI: 10.1200/JCO.2009.22.9088. View

13.

Estey E, Thall P, Pierce S, Cortes J, Beran M, Kantarjian H . Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999; 93(8):2478-84. View

14.

Nazha A, Bueso-Ramos C, Estey E, Faderl S, OBrien S, Fernandez M . The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013; 3:218. PMC: 3764477. DOI: 10.3389/fonc.2013.00218. View

15.

Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen B, Bruserud O . In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs. 2008; 17(11):1623-33. DOI: 10.1517/13543784.17.11.1623. View

16.

Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S . MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007; 110(5):1639-47. DOI: 10.1182/blood-2007-03-080523. View

17.

Ablain J, de The H . Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011; 117(22):5795-802. DOI: 10.1182/blood-2011-02-329367. View

18.

de The H, Chen Z . Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010; 10(11):775-83. DOI: 10.1038/nrc2943. View

19.

Gupta K, Gulen F, Sun L, Aguilera R, Chakrabarti A, Kiselar J . GSK3 is a regulator of RAR-mediated differentiation. Leukemia. 2012; 26(6):1277-85. PMC: 4458365. DOI: 10.1038/leu.2012.2. View

20.

Luo P, Lin M, Li L, Yang B, He Q . The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. PLoS One. 2011; 6(11):e27298. PMC: 3210155. DOI: 10.1371/journal.pone.0027298. View